Real-life data on pasireotide in monotherapy or combined in active Cushing's disease. [PDF]
Mondin A +6 more
europepmc +1 more source
Aggressive Macroprolactinoma Refractory to Multiple Lines of Localized and Systemic Therapy. [PDF]
Konindala N, Paluri R, Darapu H.
europepmc +1 more source
Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages. [PDF]
Václav H +11 more
europepmc +1 more source
Recurrent pituitary apoplexy: experience from a national registry and review of the literature. [PDF]
Biagetti B +9 more
europepmc +1 more source
Secondary Loss of Response to Dopamine Receptor Agonists in the Treatment of Macroprolactinoma. [PDF]
Alkundi A, Momoh R.
europepmc +1 more source
Microprolactinoma (Pituitary Adenoma) as a Cause of Secondary Headache in a Pediatric Patient With Pain and Restricted Mouth Opening: A Case Report. [PDF]
Draghici R +3 more
europepmc +1 more source
Pregnancy and delivery after surgical remission in women with prolactinomas desiring pregnancy: Refining surgical indications. [PDF]
Amano K +6 more
europepmc +1 more source
Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas? [PDF]
Agrawal N +11 more
europepmc +1 more source
Effect of cabergoline on the management of diabetes mellitus: a systematic review and meta-analysis. [PDF]
Khorasani S +5 more
europepmc +1 more source

